創薬アウトソーシング市場：サービスタイプ別、創薬フェーズ別、ワークフロー別、薬剤タイプ別、適用領域別、エンドユーザー別-2025-2030年世界予測

創薬アウトソーシング市場の2024年の市場規模は39億6,000万米ドルで、2025年には42億9,000万米ドル、CAGR 8.44％で成長し、2030年には64億5,000万米ドルに達すると予測されています。

世界の製薬業界は急速に進化しており、創薬アウトソーシングは革新的な治療と開発期間の短縮を可能にする重要な手段として浮上しています。今日の競合環境において、企業は深い科学的専門知識、最先端技術、コスト効率を活用するために、外部の専門組織と提携するケースが増えています。この戦略的転換により、企業はコアコンピタンスに集中できるだけでなく、高度なアッセイ開発から高度なデータ解析まで、幅広い技術能力を利用できるようになります。創薬のダイナミックな性質は、規制の枠組みの強化や研究開発費の増大と相まって、コラボレーションを贅沢なものとするのではなく、必要なものにしています。アウトソーシングは、従来の社内モデルにおけるリソースの制約や断片的なスキルセットといった課題を克服する上で不可欠であることが証明されています。業界が技術革新のペースを維持しようと努力する中、利害関係者は、スピード、正確さ、外部の専門知識を重視する市場に絶えず適応しています。業務モデルの変革は、機動的かつ共同研究の新時代の到来を告げるものであり、創薬アウトソーシングを次世代治療薬開発の礎石として位置づけるものです。この包括的な概観は、業界の将来を形作る動向と戦略的洞察の深堀りにつながるものです。

創薬アウトソーシング市場の変革

創薬アウトソーシングのエコシステムは、急速な技術進歩や進化する科学的手法に後押しされ、変革的なシフトを経験しています。業界をリードする企業各社は、高度な分析能力と合理化された調査プロセスを提供するデジタルツールを採用し、革新的な治療法の上市に要する時間を短縮しています。従来の調査モデルは、自動化、人工知能、ハイスループットスクリーニングを統合したプラットフォームによって覆されつつあり、より正確な予測と迅速な意思決定が可能となっています。地理的な境界が曖昧になり、地域を超えたコラボレーションによって多様な専門知識が結集される中、グローバリゼーションは重要な役割を果たしています。規制要件が複雑化するにつれ、データの完全性とコンプライアンスを確保しながら厳格な基準を乗り切るには、専門能力を備えた外部パートナーの存在がますます重要になっています。さらに、個別化医療やターゲット主導型研究が重視されるようになり、企業はより柔軟で迅速なアウトソーシング戦略を採用せざるを得なくなっています。このシフトは単に業務戦術の変更ではなく、科学的発見へのアプローチ方法の根本的な再考を意味します。この進化は、俊敏なパートナーシップと、効率性と画期的な成果の両方を達成するための革新的なソリューションの必要性を強調しています。

創薬アウトソーシングにおける主要なセグメンテーションの洞察

包括的なセグメンテーションアプローチにより、創薬アウトソーシング市場のニュアンスを理解し、その成長を促進する多様な側面を浮き彫りにします。サービスタイプに基づく分析では、市場を生物学的サービス、化学的サービス、データ管理サービスに区分しています。このセグメンテーションでは、生物学的サービスはアッセイ開発と生物学的試験に、化学的サービスはカスタム合成とプロセス研究開発に細分化されています。データマネジメントサービスは、バイオインフォマティクスとデータ統合のレンズを通して分析され、データ駆動型戦略がいかに研究の全段階をサポートしているかを示しています。探索段階の観点から見ると、市場はリード最適化とターゲット同定に分かれ、リード最適化はさらに化合物スクリーニングと構造ベースのドラッグデザインに分類され、ターゲット同定はバイオマーカー探索とゲノム配列決定法に分かれます。ワークフローのセグメンテーションは、リードの同定と候補の最適化から前臨床開発、ターゲットの同定とスクリーニング、そして最終的には機能インフォマティクスと組み合わせたターゲットのバリデーションに至る連続性を捉えています。さらに、薬物タイプのセグメンテーションでは、高分子と低分子を区別し、高分子は生物学的製剤とバイオシミラー評価の特定領域を通して検討します。応用分野のセグメンテーションでは、心血管疾患、感染症、腫瘍などの治療領域が調査され、各領域では、心血管疾患では心不全や高血圧、感染症では細菌感染やウイルス感染、腫瘍では血液悪性腫瘍や固形腫瘍などの病態がさらに詳細に調査されます。最後に、エンドユーザー別のセグメンテーションでは、契約研究機関、製薬・バイオテクノロジー企業、研究機関に焦点を当て、前者はフルサービス型と専門モデルにさらに分けられ、後者は学術機関と政府研究センターを対比しています。このように多層的なセグメンテーションを行うことで、新たな市場の要求と多様な利害関係者の期待に応える技術的枠組みが固まる。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で消費者の慢性疾患罹患率が上昇
    • 新薬と個別化医療の需要の高まり
    • 世界中の製薬会社の研究開発費の増加
  • 抑制要因
    • 創薬プロセスのアウトソーシングに伴う高コスト
  • 機会
    • 新薬の開発と検証のための学術機関との継続的な提携
    • AIと機械学習を活用した創薬プロセスの効率化
  • 課題
    • 創薬アウトソーシングパートナーシップにおける重要なプロセスへの依存リスク
• 市場セグメンテーション分析
  • サービスタイプ：ハイスループットスクリーニングと自動化の革新により、生物学的サービスの需要が高まっています。
  • 応用分野：効果的な治療法の開発を促進するために、心血管疾患におけるアウトソーシングサービスの大幅な導入
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 創薬アウトソーシング市場：サービスタイプ別

• 生物学的サービス
  • アッセイ開発
  • 生物学的試験
• 化学サービス
  • カスタム合成
  • プロセス研究開発
• データ管理サービス
  • バイオインフォマティクス
  • データ統合

第7章 創薬アウトソーシング市場発見フェーズ別

• リード最適化
  • 化合物スクリーニング
  • 構造に基づく医薬品設計
• ターゲット識別
  • バイオマーカーの発見
  • ゲノムシーケンシング法

第8章 創薬アウトソーシング市場：ワークフロー別

• リード特定と候補者最適化
• 前臨床開発
• ターゲットの特定とスクリーニング
• ターゲット検証と機能情報科学

第9章 創薬アウトソーシング市場薬剤の種類別

• 巨大分子
  • 生物学的製剤
  • バイオシミラー
• 小分子

第10章 創薬アウトソーシング市場：応用分野別

• 心血管疾患
  • 心不全
  • 高血圧
• 感染症
  • 細菌感染症
  • ウイルス感染
• 腫瘍学
  • 造血悪性腫瘍
  • 固形腫瘍

第11章 創薬アウトソーシング市場：エンドユーザー別

• 契約調査機関
  • フルサービスCRO
  • 専門CRO
• 製薬・バイオテクノロジー企業
  • 大企業
  • 中小企業
• 調査機関
  • 学術機関
  • 政府研究センター

第12章 南北アメリカの創薬アウトソーシング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の創薬アウトソーシング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの創薬アウトソーシング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies Inc.
• Aragen Life Sciences Ltd.
• BPS Bioscience, Inc.
• Celentyx Ltd.
• Charles River Laboratories International, Inc.
• Covance, Inc.
• Crown Bioscience, Inc.
• Curia Global, Inc.
• Dalton Pharma Services
• Eurofins Scientific
• Evotec SE
• Explicyte
• GenScript Biotech Corporation
• HD Biosciences Co., Ltd.
• IQVIA
• Jubilant Biosys Ltd.
• Laboratory Corporation of America Holdings
• Merck & Co., Inc.
• Oncodesign Services
• Personalis, Inc.
• Pfizer Inc.
• PPD Inc.
• Promega Corporation
• Revvity Discovery Limited
• Sanofi S.A.
• STC Biologics Inc.
• Syngene International Ltd.
• TCG Lifesciences Pvt. Limited
• Thermo Fisher Scientific Inc.
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. DRUG DISCOVERY OUTSOURCING MARKET MULTI-CURRENCY
• FIGURE 2. DRUG DISCOVERY OUTSOURCING MARKET MULTI-LANGUAGE
• FIGURE 3. DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
• FIGURE 4. DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 82. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 83. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 84. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 91. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 92. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 93. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 95. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 96. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 97. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 98. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 101. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 102. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 103. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 105. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 106. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 108. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 109. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 110. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 111. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 113. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 114. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 115. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 119. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 120. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 121. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 123. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 124. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 125. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 126. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 127. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 128. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 129. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 131. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 132. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 134. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 137. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 138. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 139. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 141. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 142. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 143. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 144. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 145. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 146. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 147. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 149. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 150. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 151. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 152. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 153. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 155. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 156. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 157. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 159. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 160. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 161. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 162. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 163. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 164. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 165. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 167. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 168. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 170. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 173. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 174. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 175. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 176. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 178. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 179. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 180. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 181. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 182. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 184. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 186. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 188. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 192. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 194. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 195. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 196. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 197. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 198. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 199. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 200. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 201. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 202. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 203. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 204. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 205. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 206. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 207. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 208. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 211. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 212. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 213. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 215. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 216. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 217. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 218. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 219. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 220. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 221. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 222. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 223. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 224. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 225. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 226. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 229. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 230. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 231. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 233. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 234. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 235. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 236. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 237. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 238. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 239. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 240. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 241. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 242. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 243. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 244. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 245. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 247. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 248. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 249. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 250. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 251. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 252. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 254. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 255. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 256. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 257. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 258. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 259. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 260. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 261. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 262. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 264. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 265. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 266. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 267. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 268. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 269. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 270. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 271. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 272. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 273. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 274. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 275. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 276. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 277. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 278. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 279. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 280. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 282. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 283. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 284. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 285. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 286. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 287. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 288. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 289. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
• TABLE 290. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
• TABLE 291. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
• TABLE 292. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 293. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 294. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
• TABLE 295. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
• TABLE 296. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 297. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 298. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 299. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 300. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
• TABLE 301. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
• TABLE 302. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 303. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 304. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 305. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
• TABLE 306. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
• TABLE 307. PHILIPPINES DRUG

The Drug Discovery Outsourcing Market was valued at USD 3.96 billion in 2024 and is projected to grow to USD 4.29 billion in 2025, with a CAGR of 8.44%, reaching USD 6.45 billion by 2030.

The global pharmaceutical landscape is evolving rapidly, and drug discovery outsourcing has emerged as a crucial enabler for innovative therapies and accelerated timelines. In today's competitive environment, companies are increasingly partnering with specialized external organizations to leverage deep scientific expertise, state-of-the-art technology, and cost efficiencies. This strategic shift not only allows organizations to focus on their core competencies but also provides access to a broad spectrum of technical capabilities, from advanced assay development to sophisticated data analysis. The dynamic nature of drug discovery, combined with tightening regulatory frameworks and increasing R&D expenditures, makes collaboration a necessity rather than a luxury. Outsourcing has proven essential in overcoming challenges such as resource constraints and fragmented skill sets within traditional in-house models. As the industry strives to maintain its pace of innovation, stakeholders are continuously adapting to a market that prizes speed, precision, and external expertise. The transformation in operational models heralds a new era of agile and collaborative research, positioning drug discovery outsourcing as a cornerstone in the development of next-generation therapeutics. This comprehensive overview sets the stage for a deeper exploration of the trends and strategic insights that are shaping the future of the industry.

Transformative Shifts in the Drug Discovery Outsourcing Landscape

The drug discovery outsourcing ecosystem is experiencing transformative shifts fueled by rapid technological advancement and evolving scientific methodologies. Industry leaders are embracing digital tools that offer enhanced analytic capabilities and streamlined research processes, thereby reducing the time required to bring innovative therapies to market. Traditional models of research are being upended by integrated platforms that merge automation, artificial intelligence, and high-throughput screening, enabling more accurate predictions and faster decision-making. Globalization plays a significant role, as geographical boundaries blur and collaboration across regions brings diverse expertise together. As regulatory requirements become more complex, external partners with specialized capabilities are increasingly critical in navigating stringent standards while ensuring data integrity and compliance. Moreover, the growing emphasis on personalized medicine and target-driven research is compelling organizations to adopt a more flexible and responsive outsourcing strategy. The shift is not merely a change in operational tactics but represents a fundamental rethinking of how scientific discovery is approached. This evolution underscores the need for agile partnerships and innovative solutions geared toward achieving both efficiency and breakthrough outcomes.

Key Segmentation Insights in Drug Discovery Outsourcing

A comprehensive segmentation approach provides a nuanced understanding of the drug discovery outsourcing market, highlighting the diverse facets that drive its growth. An analysis based on service type dissects the market into Biological Services, Chemical Services, and Data Management Services. In this segmentation, Biological Services come with a further breakdown into assay development and biological testing, while Chemical Services are refined into custom synthesis and process R&D. Data Management Services are analyzed through the lenses of bioinformatics and data integration, showing how data-driven strategies support all stages of research. When viewed from the perspective of discovery phase, the market divides into lead optimization and target identification, with lead optimization further categorized into compound screening and structure-based drug design, and target identification split into biomarker discovery and genomic sequencing methods. The workflow segmentation captures a continuum that spans from lead identification and candidate optimization to preclinical development, target identification and screening, and ultimately, target validation paired with functional informatics. Additionally, drug type segmentation distinguishes between large molecules and small molecules, wherein large molecules are examined through the specific areas of biologics and biosimilar evaluation. Application area segmentation explores therapeutic domains such as cardiovascular diseases, infectious diseases, and oncology, with each area further detailed to address conditions like heart failure and hypertension in cardiovascular, bacterial and viral infections in infectious diseases, and hematological malignancies along with solid tumors in oncology. Lastly, segmentation by end user focuses on contract research organizations, pharmaceutical and biotechnology companies, and research institutes, with the former further divided into full-service and specialty models, and the latter contrasting academic institutions against government research centers. This multilayered segmentation solidifies a technical framework that caters to emerging market demands and diverse stakeholder expectations.

Based on Service Type, market is studied across Biological Services, Chemical Services, and Data Management Services. The Biological Services is further studied across Assay Development and Biological Testing. The Chemical Services is further studied across Custom Synthesis and Process R&D. The Data Management Services is further studied across Bioinformatics and Data Integration.

Based on Discovery Phase, market is studied across Lead Optimization and Target Identification. The Lead Optimization is further studied across Compound Screening and Structure-Based Drug Design. The Target Identification is further studied across Biomarker Discovery and Genomic Sequencing Methods.

Based on Workflow, market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics.

Based on Drug Type, market is studied across Large Molecules and Small Molecules. The Large Molecules is further studied across Biologics and Biosimillar.

Based on Application Area, market is studied across Cardiovascular Diseases, Infectious Diseases, and Oncology. The Cardiovascular Diseases is further studied across Heart Failure and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors.

Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Institutes. The Contract Research Organizations is further studied across Full-Service CROs and Specialty CROs. The Pharmaceutical & Biotechnology Companies is further studied across Large Enterprises and SMEs. The Research Institutes is further studied across Academic Institutions and Government Research Centers.

Key Regional Trends and Market Dynamics

Global trends in drug discovery outsourcing reveal distinct regional dynamics that influence market strategies and investment decisions. In the Americas, robust infrastructure, high R&D investment, and an integrated ecosystem of biotech startups and established pharmaceutical entities lay the foundation for intensive research collaborations and innovative solutions. This region's strategic focus on digital transformation and regulatory excellence reinforces its position as a global leader in outsourcing partnerships. Across Europe, the Middle East, and Africa, varying economic conditions and regulatory landscapes present both challenges and opportunities. This region benefits from a blend of historical research expertise and emerging biotech hubs, which collectively drive demand for specialized services. Enhanced government initiatives and funding programs are catalyzing industry growth, while partnerships with global research organizations continue to bridge gaps between technology and clinical application. In the Asia-Pacific, rapid economic growth, increasing research expenditures, and a burgeoning talent pool are propelling the market into new frontiers. The region is witnessing strong investments in infrastructure and innovation, which, when paired with competitive cost structures, create an advantageous environment for outsourcing. Each region exhibits unique strengths and practical challenges, yet all demonstrate an unwavering commitment to advancing drug discovery through strategic collaborations and technology-driven processes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights and Market Leadership

A multitude of companies are setting benchmarks by driving innovation and quality in the drug discovery outsourcing arena. Market pioneers such as Agilent Technologies Inc. and Aragen Life Sciences Ltd. combine deep domain expertise with advanced technological platforms to deliver robust research solutions. Firms like BPS Bioscience, Inc. and Celentyx Ltd. are known for their agile approaches that integrate cutting-edge biological and chemical services, while Charles River Laboratories International, Inc. and Covance, Inc. leverage their extensive global networks to provide comprehensive, end-to-end drug development support. Other players including Crown Bioscience, Inc. and Curia Global, Inc. exemplify how data integration and specialized workflows can enhance research outcomes. Companies such as Dalton Pharma Services and Eurofins Scientific push the boundaries of chemical research with innovative process R&D, whereas Evotec SE and Explicyte are recognized for their prowess in streamlining lead optimization and target identification strategies. Leaders such as GenScript Biotech Corporation and HD Biosciences Co., Ltd. continue to redefine standards within the bioinformatics space with their data-centric approaches. Prominent names including IQVIA and Jubilant Biosys Ltd. are underscored by their vast industry experience and transformative service models. Laboratory Corporation of America Holdings, Merck & Co., Inc., Oncodesign Services, Personalis, Inc., Pfizer Inc., PPD Inc., Promega Corporation, Revvity Discovery Limited, Sanofi S.A., STC Biologics Inc., Syngene International Ltd., TCG Lifesciences Pvt. Limited, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd. further solidify the competitive landscape with their persistent innovation and collaborative strategies. These organizations are not only aligning with current market needs but are also actively shaping the future of drug discovery outsourcing.

The report delves into recent significant developments in the Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies Inc., Aragen Life Sciences Ltd., BPS Bioscience, Inc., Celentyx Ltd., Charles River Laboratories International, Inc., Covance, Inc., Crown Bioscience, Inc., Curia Global, Inc., Dalton Pharma Services, Eurofins Scientific, Evotec SE, Explicyte, GenScript Biotech Corporation, HD Biosciences Co., Ltd., IQVIA, Jubilant Biosys Ltd., Laboratory Corporation of America Holdings, Merck & Co., Inc., Oncodesign Services, Personalis, Inc., Pfizer Inc., PPD Inc., Promega Corporation, Revvity Discovery Limited, Sanofi S.A., STC Biologics Inc., Syngene International Ltd., TCG Lifesciences Pvt. Limited, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders intent on capitalizing on the evolving landscape of drug discovery outsourcing, a proactive approach is imperative. It is crucial to invest in advanced technologies that enable seamless data sharing, real-time analytics, and automation of complex processes. Embracing digital transformation and integrated platforms can lead to more efficient workflows and improved research outcomes. Strategic partnerships remain a cornerstone of success; collaborating with firms that excel in complementary services can create synergies that drive innovation and reduce time-to-market. Companies should also focus on cultivating agile operational models that quickly adapt to emerging scientific discoveries and regulatory changes. Establishing dedicated centers for digital innovation and continuous upskilling ensures that teams are well-equipped to handle the rapidly shifting paradigms of research. Leaders are encouraged to invest in a robust network of global partners, particularly in regions with unique expertise and cost-effective solutions, to diversify risk and broaden scientific capabilities. Emphasizing quality control, compliance, and transparent communication throughout the outsourced process not only builds trust but also fortifies market reputation. These actionable steps form the cornerstone of a strategy that is both forward-looking and resilient, positioning organizations to thrive amid the complexities of modern drug discovery.

Conclusion: Strategic Navigations in Drug Discovery Outsourcing

In summary, the drug discovery outsourcing market is characterized by rapid innovation and strategic shifts that redefine traditional research paradigms. By leveraging advanced technologies and fostering global collaborations, organizations can navigate the intricacies of modern drug development with confidence. The multi-dimensional segmentation of the market, detailed from service type to end user, provides a granular view that aids in the crafting of targeted strategies. Regional and company-specific insights further highlight the dynamic interplay of technological advancements, regulatory influences, and market demands. As stakeholders continue to adapt to these transformative trends, the emphasis on agility, innovation, and strategic partnerships is more pronounced than ever. This exploration underlines the necessity for a comprehensive, adaptable approach to drive both efficiency and breakthrough results in drug discovery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases among consumers globally
    • 5.1.1.2. Growing demand for novel drugs and personalized medicine
    • 5.1.1.3. Increasing R&D expenditure by pharmaceutical companies worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with outsourcing drug discovery processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing partnerships with academic institutions for novel drug development and validation
    • 5.1.3.2. Leveraging AI and machine learning in streamlining drug discovery processes
  • 5.1.4. Challenges
    • 5.1.4.1. Dependency risks over critical processes in drug discovery outsourcing partnerships
• 5.2. Market Segmentation Analysis
  • 5.2.1. Service Type : Growing demand for biological services due to innovations in high-throughput screening and automation
  • 5.2.2. Application Area : Significant adoption of outsourcing services in cardiovascular diseases to expedite the development of effective treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Discovery Outsourcing Market, by Service Type

• 6.1. Introduction
• 6.2. Biological Services
  • 6.2.1. Assay Development
  • 6.2.2. Biological Testing
• 6.3. Chemical Services
  • 6.3.1. Custom Synthesis
  • 6.3.2. Process R&D
• 6.4. Data Management Services
  • 6.4.1. Bioinformatics
  • 6.4.2. Data Integration

7. Drug Discovery Outsourcing Market, by Discovery Phase

• 7.1. Introduction
• 7.2. Lead Optimization
  • 7.2.1. Compound Screening
  • 7.2.2. Structure-Based Drug Design
• 7.3. Target Identification
  • 7.3.1. Biomarker Discovery
  • 7.3.2. Genomic Sequencing Methods

8. Drug Discovery Outsourcing Market, by Workflow

• 8.1. Introduction
• 8.2. Lead Identification & Candidate Optimization
• 8.3. Preclinical Development
• 8.4. Target Identification & Screening
• 8.5. Target Validation & Functional Informatics

9. Drug Discovery Outsourcing Market, by Drug Type

• 9.1. Introduction
• 9.2. Large Molecules
  • 9.2.1. Biologics
  • 9.2.2. Biosimillar
• 9.3. Small Molecules

10. Drug Discovery Outsourcing Market, by Application Area

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
  • 10.2.1. Heart Failure
  • 10.2.2. Hypertension
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial Infections
  • 10.3.2. Viral Infections
• 10.4. Oncology
  • 10.4.1. Hematological Malignancies
  • 10.4.2. Solid Tumors

11. Drug Discovery Outsourcing Market, by End User

• 11.1. Introduction
• 11.2. Contract Research Organizations
  • 11.2.1. Full-Service CROs
  • 11.2.2. Specialty CROs
• 11.3. Pharmaceutical & Biotechnology Companies
  • 11.3.1. Large Enterprises
  • 11.3.2. SMEs
• 11.4. Research Institutes
  • 11.4.1. Academic Institutions
  • 11.4.2. Government Research Centers

12. Americas Drug Discovery Outsourcing Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Drug Discovery Outsourcing Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Drug Discovery Outsourcing Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Accenture's strategic investment in 1910 Genetics revolutionizes biopharma drug discovery with AI innovation
  • 15.3.2. Agilent to acquire drug services company BioVectra for close to USD 1 billion
  • 15.3.3. Evotec and Pfizer announce drug discovery collaboration
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies Inc.
• 2. Aragen Life Sciences Ltd.
• 3. BPS Bioscience, Inc.
• 4. Celentyx Ltd.
• 5. Charles River Laboratories International, Inc.
• 6. Covance, Inc.
• 7. Crown Bioscience, Inc.
• 8. Curia Global, Inc.
• 9. Dalton Pharma Services
• 10. Eurofins Scientific
• 11. Evotec SE
• 12. Explicyte
• 13. GenScript Biotech Corporation
• 14. HD Biosciences Co., Ltd.
• 15. IQVIA
• 16. Jubilant Biosys Ltd.
• 17. Laboratory Corporation of America Holdings
• 18. Merck & Co., Inc.
• 19. Oncodesign Services
• 20. Personalis, Inc.
• 21. Pfizer Inc.
• 22. PPD Inc.
• 23. Promega Corporation
• 24. Revvity Discovery Limited
• 25. Sanofi S.A.
• 26. STC Biologics Inc.
• 27. Syngene International Ltd.
• 28. TCG Lifesciences Pvt. Limited
• 29. Thermo Fisher Scientific Inc.
• 30. WuXi AppTec Co., Ltd.